The cardiovascular area is the prime cause of human mortalities throughout the world. Solvay Phamaceuticals is seeking to attain a prominent position in the field of cardiometabolics.

With the acquisition of Fournier Pharma, Solvay Pharmaceuticals has now become the global leader in fenofibrate, a successful cardiometabolic product for treating raised blood lipids.

The integration of Fournier activities adds a strong and unique dyslipidemia (control of cholesterol and triglycerides) product line to Solvay’s existing cardiology business, making this new cardiometabolic area the group’s largest franchise.